Coutellier A, Bonnefont-Rousselot D, Delattre J, Lopez O, Jaudon M C, Herson S, Emerit J
Service de Médecine interne, Hôpital de La Salpêtrière, Paris.
Presse Med. 1992 Nov 14;21(38):1809-12.
Among 29 seropositive subjects who had participated in the HIV 87 therapeutic trial (Mérieux laboratories), the oxidative stress was evaluated at 24 months in 16 treated with diethyldithiocarbamate (dithiocarb) and in 13 who had received the placebo. No significant difference was found between these two groups, whereas the existence of an oxidative stress has been confirmed in seropositive subjects compared with controls.
在参与了HIV 87治疗试验（梅里埃实验室）的29名血清反应阳性受试者中，对16名接受二乙基二硫代氨基甲酸盐（二硫代氨基甲酸盐）治疗的受试者和13名接受安慰剂治疗的受试者在24个月时进行了氧化应激评估。这两组之间未发现显著差异，而与对照组相比，血清反应阳性受试者中氧化应激的存在已得到证实。
